Effect of Tiagabine on Sleep in Elderly Subjects With Primary Insomnia: A Randomized, Double-Blind, Placebo-Controlled Study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
SUBJECT OBJECTIVE: This study further evaluated the effects of tiagabine on sleep in elderly subjects with primary insomnia. METHODS: Elderly subjects (aged 65-85 years) meeting DSM-IV-TR criteria for primary insomnia were randomly assigned to receive tiagabine 2, 4, 6, or 8 mg or placebo on 2 consecutive nights. Efficacy was assessed using standard polysomnography and a postsleep questionnaire. Additional assessments included the Assessment of Daily Functioning, Digit Symbol Substitution Test (for residual effects), and visual analog scale (for sleepiness/alertness). RESULTS: A total of 207 subjects were randomly assigned to study medication (tiagabine: 2 mg, n = 43; 4 mg, n = 38; 6 mg, n = 45; 8 mg, n = 43; placebo, n = 38). Tiagabine did not significantly effect wake after sleep onset, latency to persistent sleep, or total sleep time compared with placebo (P > .05). Significant increases in Stage 3+4 sleep (i.e., slow-wave sleep) were found for tiagabine 4, 6, and 8 mg versus placebo, with a corresponding significant decrease in Stage 1 sleep (P < .05). At 6 and 8 mg, tiagabine also significantly reduced the number of awakenings and increased the ratio of Stage 3+4/(Stage 1 +wake after sleep onset). In general, there were no significant effects on subjects' ratings of sleep or daily functioning with tiagabine 2, 4, and 6 mg versus placebo. These 3 doses had tolerability profiles comparable with that of placebo and were not associated with significant residual effects or reduced alertness. The 8-mg dose, however, significantly decreased subjective total sleep time and refreshing quality of sleep, as well as daily functioning. This dose was associated with troublesome adverse events, significant residual effects, and reduced alertness. CONCLUSIONS: In elderly subjects with primary insomnia, tiagabine did not have a significant effect on wake after sleep onset, latency to persistent sleep, total sleep time, or the subjective rating of sleep. Tiagabine 4, 6, and 8 mg significantly increased slow-wave sleep, with a corresponding significant decrease in Stage 1 sleep. Tiagabine was generally well tolerated, with doses of less than 6 mg having tolerability profiles generally similar to that of placebo. The 8-mg dose, however, was associated with troublesome adverse events, residual effects, and reduced alertness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The meaning of good sleep: a longitudinal study of polysomnography and subjective sleep quality
ÅKERSTEDT, T., HUME, K., MINORS, D., & WATERHOUSE, J. (1994) · Journal of Sleep Research · doi:10.1111/j.1365-2869.1994.tb00122.x · Cited by 298 · cited 1×
“Dizziness 1 (3) 0 (0) 1 (3) 3 (7) 10 (23) Nausea 0 (0) 0 (0) 1 (3) 0 (0) 7 (16) Headache 1 (3) 1 (2) 1 (3) 1 (2) 2 (5)”
Lancel, M. (1999) · Sleep · doi:10.1093/sleep/22.1.33 · Cited by 240
Learning and sleep: the sequential hypothesis
Ambrosini, M. V., & Giuditta, A. (2001) · Sleep Medicine Reviews · doi:10.1053/smrv.2001.0180 · Cited by 108 · cited 1×
“Dizziness 1 (3) 0 (0) 1 (3) 3 (7) 10 (23) Nausea 0 (0) 0 (0) 1 (3) 0 (0) 7 (16) Headache 1 (3) 1 (2) 1 (3) 1 (2) 2 (5)”
Cited by
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Morin, C. M., & Benca, R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60750-2 · Cited by 976
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Sleep Disturbance in Bipolar Disorder: Therapeutic Implications
Plante, D. T., & Winkelman, J. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08010077 · Cited by 268
“Similarly, tiagabine may increase slow-wave sleep, although its usefulness as a hypnotic in primary insomnia is limited (140).”
BackgroundEnhancement of slow wave sleep: Implications for insomnia
Walsh, J. K. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.5.2s.s27 · Cited by 86
Self-citation
Metadata
- Authors
- Roth, T., Wright, K. P., & Walsh, J.
- Venue
- Sleep
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-03
- Volume
- 29
- Issue
- 3
- Pages
- 335-341
- ISSN
- 0161-8105 (ISSN-L)
- 1550-9109
- OpenAlex
- W2150713542
- Cited by
- 74
- References
- 3
- FWCI
- 10.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.